Ergocalciferol

Provitamin D2 Compound — ALIMENTARY TRACT AND METABOLISM

Key facts

Ergocalciferol is an ofp drug in the Provitamin D2 Compound class catalogued in DrugCentral. It was first approved by the FDA in 1941. DrugCentral lists 3 molecular targets, including CYP27B1, VDR and CYP2R1. Recorded indications include Familial x-linked hypophosphatemic vitamin D refractory rickets, Glucocorticoid Induced Osteoporosis, Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis and Hypocalcemia.

• Approval status: ofp (first approved 1941 by the FDA).
• Drug class: Provitamin D2 Compound.
• Molecular targets: CYP27B1, VDR and CYP2R1 (3 listed in DrugCentral).
• Indications: Familial x-linked hypophosphatemic vitamin D refractory rickets, Glucocorticoid Induced Osteoporosis, Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis, Hypocalcemia and Hypogonadal Osteoporosis in Males and others.
• ATC code: A11CC01 (Vitamin D and analogues).
• Molecular formula: C28H44O; molecular weight 396.66 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (15)

• Familial x-linked hypophosphatemic vitamin D refractory rickets
• Glucocorticoid Induced Osteoporosis
• Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis
• Hypocalcemia
• Hypogonadal Osteoporosis in Males
• Hypoparathyroidism
• Osteomalacia
• Osteoporosis
• Postmenopausal osteoporosis
• Prevention of dental caries
• Rickets
• Vitamin D deficiency
• Vitamin D Dependent Rickets
• Vitamin deficiency
• Vitamin Deficiency Prevention

Off-label uses (3)

• Anticonvulsant-induced Osteomalacia
• Hyperparathyroidism Secondary to Chronic Renal Failure
• Renal osteodystrophy

Contraindications (50)

• Achalasia of esophagus
• Acute nephropathy
• Acute peptic ulcer
• Anemia due to enzyme deficiency
• Arteriosclerosis obliterans
• Aseptic necrosis of bone of jaw
• Atrial fibrillation
• Bed-ridden
• Blood coagulation disorder
• Carcinoma of female breast
• Central nervous system depression
• Constipation
• Dehydration
• Dental fluorosis
• Diabetes mellitus
• Diarrhea
• Disease of liver
• Duodenitis
• Dysphagia
• Esophageal dysmotility
• Esophageal Obstruction
• Esophagitis
• Fracture of femur
• Gastritis
• Hb SS disease
• Hemochromatosis
• High Grade Dysplasia associated with Barrett's Esophagus
• Hypercalcemia
• Hypercalciuria
• Hyperlipidemia
• + 20 more

Mechanism & targets

• Established pharmacologic class: Provitamin D2 Compound

Molecular targets (3)

Target	Gene	Action	Activity
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	CYP27B1	unknown	—
Vitamin D3 receptor	VDR	agonist	—
Vitamin D 25-hydroxylase	CYP2R1	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1941-01-11	FDA	—	SANOFI AVENTIS US

ATC classification

ATC code	Therapeutic hierarchy
A11CC01	ALIMENTARY TRACT AND METABOLISM › VITAMINS › VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO › Vitamin D and analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Toxicity to various agents	2067.6
Drug interaction	1298.2
Completed suicide	1049.4
Acute kidney injury	1020.5
Drug abuse	802.1
Intentional overdose	730.4
Overdose	700.6
Thrombocytopenia	657.4
Product dose omission issue	615.5
Fatigue	572.3
Multiple sclerosis relapse	567.5
Febrile neutropenia	565.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ergocalciferol is on its molecule page.

• Molecular formula: C₂₈H₄₄O
• Molecular weight: 396.66 g/mol
• CAS number: 50-14-6
• InChIKey: MECHNRXZTMCUDQ-RKHKHRCZSA-N
• PubChem CID: 5280793

CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ergocalciferol used for?

DrugCentral lists the following indications for Ergocalciferol: Familial x-linked hypophosphatemic vitamin D refractory rickets, Glucocorticoid Induced Osteoporosis, Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis, Hypocalcemia, Hypogonadal Osteoporosis in Males, Hypoparathyroidism, Osteomalacia and Osteoporosis and others.

How does Ergocalciferol work?

Its molecular targets in DrugCentral include CYP27B1, VDR (agonist) and CYP2R1.

When was Ergocalciferol first approved?

Ergocalciferol was first approved by the FDA in 1941.

What drug class does Ergocalciferol belong to?

Ergocalciferol is in the Provitamin D2 Compound class.

What is the chemical formula of Ergocalciferol?

Ergocalciferol has the molecular formula C28H44O and a molecular weight of 396.66 g/mol.

Sources

• DrugCentral drug card 2838 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1536 — compound record and bioactivity
• PubChem CID 5280793 — chemical identifiers
• DrugBank DB00153 — drug record
• FDA UNII VS041H42XC — substance identity
• DailyMed: FDA labels for Ergocalciferol — current prescribing information (label search)
• UniProt O15528 (CYP27B1) — target protein
• UniProt P11473 (VDR) — target protein
• UniProt Q6VVX0 (CYP2R1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.